AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) will present eight scientific posters through Allergan Aesthetics at AMWC Dubai, taking place October 21–23, 2026. The research covers HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic, following HArmonyCa's recent UAE launch.
In a subgroup analysis, all eight participants using GLP-1 weight-loss medications and treated with HArmonyCa showed visible midface improvement at three months; the findings are preliminary. Other data include improved patient-reported neck appearance and satisfaction after SKINVIVE treatment and satisfaction with repeated BOTOX Cosmetic treatment among Middle Eastern patients.
AbbVie (ABBV) entered a multi-year partnership with McLaren Racing to become an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team.
The partnership centers on AbbVie Race to Innovate, a campaign launching at the 2026 Formula 1 United States Grand Prix in Austin and expanding throughout the 2027 season. AbbVie will donate $10,000 for every 10 Constructors' Championship points earned by McLaren to global charities supporting people with immune-mediated diseases. Donations will support patient advocacy organizations providing education, resources and support, and will continue throughout the full 2027 season.
AbbVie (NYSE: ABBV) reported higher endoscopic remission rates with investigational ABBV-466 than either monotherapy in a Phase 2a Crohn's disease study. The ongoing, open-label TARGET-CD trial randomized 300 patients to ABBV-466, risankizumab or trosunilimab for 24 weeks. ABBV-466 combines the two therapies.
At Week 12, the primary endpoint, remission measured by bowel examination reached 30.2% with ABBV-466, versus 21.3% with risankizumab and 18.0% with trosunilimab. At Week 24, rates were 40.5%, 22.4% and 20.0%, respectively. Gene expression analyses showed intestinal tissue repair and barrier restoration at Week 12, followed by tissue remodeling and metabolic changes at Week 24. Serious adverse events occurred in 10.4% of ABBV-466 patients, versus 9.6% and 9.0% with the respective monotherapies. Results will be presented at the 2026 United European Gastroenterology Week Congress.
AbbVie (ABBV) will present new and updated solid tumor data at the ESMO Congress in Madrid on October 23–27, 2026. The program spans seven assets, including investigational treatments and approved medicines.
In Phase 1 colorectal cancer data, Temab-A plus bevacizumab showed median overall survival of 14.7 months versus 10.2 months with standard care. ABBV-706 produced a 56% response rate in a previously treated small cell lung cancer cohort. Additional findings cover Temab-A in lung cancer, ABBV-969 prostate cancer biomarkers and ABBV-1480 lung cancer treatment. Phase 3 studies of Temab-A, ABBV-706 and ABBV-1480 are ongoing. ABBV-1480 findings also identified severe treatment-related adverse events, including hypertension and proteinuria with monotherapy.
AbbVie (ABBV) announced 20 scientific abstracts on inflammatory bowel disease treatments for presentation at UEG Week in Barcelona, October 17–20, 2026. In COMMAND, SKYRIZI 180 mg produced week-96 as-observed clinical remission rates of 54.0%–73.1% and endoscopic remission rates of 38.8%–53.5% across ulcerative colitis groups with differing prior treatment exposure.
In U-ENDURE, RINVOQ 15 mg and 30 mg achieved week-144 as-observed clinical remission rates of 78.9% and 86.6%, respectively, in Crohn's disease; endoscopic remission, assessed by bowel examination, reached 47.1% and 64.2%. Interim UPlift results showed clinical response within 12 weeks in 70.2% of evaluable patients. A separate claims analysis found lower hospitalization and surgery rates after switching to RINVOQ versus another TNF inhibitor. Presentations also cover subcutaneous SKYRIZI induction and investigational ABBV-466.
AbbVie (ABBV) presented new Phase 3 AFFIRM results evaluating subcutaneous SKYRIZI induction treatment in adults with moderately to severely active Crohn's disease.
At week 12, endoscopic remission—little to no visible intestinal inflammation—was 27.7% versus 10.2% with placebo; ulcer-free endoscopy was 26.2% versus 10.2%. At week 24, rates were 35.8% versus 9.1% and 36.6% versus 9.1%, respectively. Results beyond week 12 cover only patients who responded during induction and entered maintenance. Week 24 rates in patients without prior advanced therapy failure reached 45.1% and 49.0%, respectively.
The study previously demonstrated superiority on both week 12 co-primary endpoints. Through week 24, adverse-event rates were lower than placebo, with no new safety signals. The subcutaneous induction regimen remains under FDA and European Medicines Agency review.
AbbVie (ABBV) announced new SKYRIZI and RINVOQ clinical data showing disease control in patients with inflammatory bowel disease across several studies. In Phase 3 AFFIRM, subcutaneous SKYRIZI produced significantly higher clinical remission and endoscopic response—improvement seen during bowel examination—than placebo at Week 12. All endpoint rates remained numerically higher through Week 24 among clinical responders.
SKYRIZI open-label extensions reported sustained outcomes through 144 weeks in FORTIFY, 148 weeks in SEQUENCE and three years in COMMAND. In FORTIFY, 74.5% of patients with fistulizing Crohn's disease had no draining fistulas after five years. RINVOQ real-world data showed clinical and corticosteroid-free remission in 93.3% of fistulizing and 76.9% of stricturing Crohn's patients who remained on treatment. Separate six-month data showed 57% clinical remission, 58% endoscopic response and 53.6% endoscopic remission.
AbbVie (ABBV) received two FDA Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A) in colorectal and non-small cell lung cancers.
The colorectal cancer designation covers combination treatment with bevacizumab for adults with refractory, metastatic disease previously treated with fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF antibody and, if indicated, an anti-EGFR antibody. The lung cancer designation covers treatment with Temab-A alone for adults with locally advanced or metastatic, EGFR wild-type, c-Met protein-expressing, non-squamous disease after platinum-based chemotherapy and anti-PD-(L)1 antibody therapy.
Both designations were primarily based on the first-in-human M21-404 study. Temab-A has not been approved by global regulatory authorities. Its development program includes Phase 3 and Phase 2/3 studies evaluating treatment alone and in combinations.
AbbVie (ABBV) and Genmab (GMAB) announced Phase 3 results showing epcoritamab plus R-CHOP improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma.
In EPCORE DLBCL-2, the combination reduced the risk of disease progression or death by 51% versus R-CHOP alone among patients with International Prognostic Index risk scores of 2–5. The primary endpoint population, with scores of 3–5, also had a 51% reduction; both results had p-values below 0.0001. Progression-free survival measures time without disease worsening or death. AbbVie and Genmab described the combination as generally well tolerated, with safety consistent with the individual agents.
The results came from the first planned efficacy interim analysis; independent monitors recommended unblinding. The trial remains ongoing. The combination is not approved, and the companies plan to engage global regulators on next steps.
AbbVie (ABBV) and Genmab (GMAB) reported improved progression-free survival with epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
The Phase 3 EPCORE DLBCL-2 trial compared the combination with R-CHOP, a standard chemotherapy and antibody regimen, alone. In patients with International Prognostic Index (IPI) scores of 2–5, the risk of disease progression or death fell 51% (hazard ratio 0.49; p-value <0.0001). The primary endpoint population, with IPI scores of 3–5, also showed a 51% reduction. Progression-free survival measures time without disease worsening or death.
The companies described the combination as generally well tolerated, with safety consistent with the individual agents. They will engage global regulatory authorities to determine next steps and submit data for a future medical meeting. The trial remains ongoing; epcoritamab plus R-CHOP is not approved.